299 related articles for article (PubMed ID: 17440059)
41. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
42. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
[TBL] [Abstract][Full Text] [Related]
43. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
[TBL] [Abstract][Full Text] [Related]
44. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors.
Bagai R; Fan W; Ma PC
IDrugs; 2010 Jun; 13(6):404-14. PubMed ID: 20506063
[TBL] [Abstract][Full Text] [Related]
45. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
46. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
47. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
Accornero P; Lattanzio G; Mangano T; Chiarle R; Taulli R; Bersani F; Forni PE; Miretti S; Scuoppo C; Dastrù W; Christensen JG; Crepaldi T; Ponzetto C
Clin Cancer Res; 2008 Apr; 14(7):2220-6. PubMed ID: 18381964
[TBL] [Abstract][Full Text] [Related]
48. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
[TBL] [Abstract][Full Text] [Related]
50. Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice.
Bulk E; Hascher A; Liersch R; Mesters RM; Diederichs S; Sargin B; Gerke V; Hotfilder M; Vormoor J; Berdel WE; Serve H; Müller-Tidow C
Cancer Res; 2008 Mar; 68(6):1896-904. PubMed ID: 18339871
[TBL] [Abstract][Full Text] [Related]
51. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.
Potiron VA; Sharma G; Nasarre P; Clarhaut JA; Augustin HG; Gemmill RM; Roche J; Drabkin HA
Cancer Res; 2007 Sep; 67(18):8708-15. PubMed ID: 17875711
[TBL] [Abstract][Full Text] [Related]
52. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
53. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
Schluep T; Hwang J; Cheng J; Heidel JD; Bartlett DW; Hollister B; Davis ME
Clin Cancer Res; 2006 Mar; 12(5):1606-14. PubMed ID: 16533788
[TBL] [Abstract][Full Text] [Related]
54. [The actual place of anti-angiogenesis in non-small cell lung cancer].
Mennecier B
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S198-205. PubMed ID: 18235414
[TBL] [Abstract][Full Text] [Related]
55. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
56. Tumor angiogenesis of non-small cell lung cancer.
Shijubo N; Kojima H; Nagata M; Ohchi T; Suzuki A; Abe S; Sato N
Microsc Res Tech; 2003 Feb; 60(2):186-98. PubMed ID: 12539173
[TBL] [Abstract][Full Text] [Related]
57. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.
Boezio AA; Berry L; Albrecht BK; Bauer D; Bellon SF; Bode C; Chen A; Choquette D; Dussault I; Fang M; Hirai S; Kaplan-Lefko P; Larrow JF; Lin MH; Lohman J; Potashman MH; Qu Y; Rex K; Santostefano M; Shah K; Shimanovich R; Springer SK; Teffera Y; Yang Y; Zhang Y; Harmange JC
Bioorg Med Chem Lett; 2009 Nov; 19(22):6307-12. PubMed ID: 19819693
[TBL] [Abstract][Full Text] [Related]
58. Angiogenesis and fibroblast proliferation precede formation of recurrent tumors after radiation therapy in nude mice.
Hast J; Schiffer IB; Neugebauer B; Teichman E; Schreiber W; Brieger J; Kim DW; Gebhard S; Born CJ; Strugala M; Sagemüller J; Brenner W; Mann WJ; Oesch F; Thelen M; Hengstler JG
Anticancer Res; 2002; 22(2A):677-88. PubMed ID: 12014637
[TBL] [Abstract][Full Text] [Related]
59. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
60. DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer.
Moncho-Amor V; Ibañez de Cáceres I; Bandres E; Martínez-Poveda B; Orgaz JL; Sánchez-Pérez I; Zazo S; Rovira A; Albanell J; Jiménez B; Rojo F; Belda-Iniesta C; García-Foncillas J; Perona R
Oncogene; 2011 Feb; 30(6):668-78. PubMed ID: 20890299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]